nivolumab - Robuta Search

https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2019-05316&r=1 A Vaccine (Galinpepimut-S) with Nivolumab for the Treatment of Patients with WT1-Expressing... A Vaccine (Galinpepimut-S) with Nivolumab for the Treatment of Patients with WT1-Expressing Malignant Pleural Mesothelioma https://www.dana-farber.org/clinical-trials/22-041 TAZNI: A Phase I/II Combination Trial of Tazemetostat with Nivolumab and Ipilimumab for Children... This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid... https://pubmed.ncbi.nlm.nih.gov/33159426/ Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal... Real-world data analysis suggests superior efficacy of nivolumab over molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma. https://pmc.ncbi.nlm.nih.gov/articles/PMC10206273/ Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for... Intratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin... https://www.cigna.com/knowledge-center/hw/medications/nivolumab-and-hyaluronidase-nvhy-injection-a625029 Nivolumab and hyaluronidase-nvhy Injection | Cigna Nivolumab and hyaluronidase-nvhy injection is used alone or with other drugs to treat certain types of cancer, including the following: melanoma (a type of... nivolumab hyaluronidase injection cigna https://www.mdanderson.org/newsroom/archived-news/ipilimumab-heavy-immunotherapy-combination-with-nivolumab-produces-high-response-rate-in-metastatic-bladder-cancer.h00-159303045.html ARCHIVED: Ipilimumab and nivolumab immunotherapy combination produces high response rate in... An immunotherapy combination with a higher dose of ipilimumab produced a 38 percent overall response rate for patients with metastatic bladder cancer in a... response rate archived ipilimumab nivolumab immunotherapy https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2018.00813/full Frontiers | Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging... In recent years, immune checkpoint inhibitors (ICIs) had a great impact in cancer therapy. ICIs display a peculiar toxicity profile, which is characterized b... thyroid dysfunction clinical presentation frontiers nivolumab induced https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-chemotherapy-previously-untreated-hodgkin-lymphoma? FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma | FDA On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine... fda approves nivolumab chemotherapy previously untreated https://content.govdelivery.com/accounts/USNIHNCI/bulletins/392b09e Nivolumab Injections | T-Cell Therapy | Disparities, 03/27/2024 t cell therapy nivolumab injections disparities https://www.frontierspartnerships.org/journals/journal-of-cutaneous-immunology-and-allergy/articles/10.3389/jcia.2026.16775/full Frontiers Publishing Partnerships | Remarkable effect of nivolumab on late liver metastasis... Jul 29, 2026 - A 58-year-old man presented with fever and anorexia. Eleven years earlier, he had undergone wide excision of a primary malignant melanoma on the left parieta... publishing partnerships frontiers remarkable effect https://research.ucc.ie/en/publications/phase-i-study-of-entinostat-and-nivolumab-with-or-without-ipilimu/ Phase I study of entinostat and nivolumab with or without ipilimumab in advanced solid tumors... https://my.clevelandclinic.org/health/drugs/19642-nivolumab-injection Nivolumab injection nivolumab injection https://www.globenewswire.com/news-release/2024/01/30/2820240/28124/en/MTG201-Nivolumab-Drug-and-Market-Analysis-2023-2032-Sales-Analytics-Clinical-Assessment-SWOT-Analysis-Emerging-Competitors.html MTG201 + Nivolumab Drug and Market Analysis 2023-2032: Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The market analysis nivolumab drug